SLE Biomarker Panels for Early Pre-Flare Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker technologies for assessing the field of autoimmune disease, immunology, and molecular biology, specifically for early detection and prevention of systemic lupus erythematosus flares, are limited by the lack of reliable and sensitive markers for predicting disease activity and flares, leading to frequent and unpredictable flare-ups.
Innovation Solution
A method for diagnosing a systemic lupus erythematosus patient involves analyzing the levels of specific biomarkers such as cytokines and chemokines, including assessing the levels of specific cytokines and chemokines, including assessing the levels of specific cytokines and chemokines, including assessing the levels of specific cytokines and chemokines, and regulatory mediators in a patient's blood or plasma sample to identify pre-flare events by evaluating the balance between inflammatory and regulatory mediators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical instruments (SELENA-SLEDAI) are used to assess disease activity, then clinical signs and symptoms can be evaluated, but early biologic signals of worsening disease cannot be detected
Solution Approach 1:
The patent measures soluble mediators (cytokines, chemokines, and other inflammatory/regulatory proteins) in advance of clinical flare to detect early biologic signals. This preliminary detection of immune dysregulation allows intervention before clinical symptoms manifest, resolving the contradiction between early detection capability and time delay.
2Speed
If rapidly acting treatment agents (steroids) are used to treat flares, then disease activity can be reduced quickly, but side effects increase
Solution Approach 1:
By detecting flare precursors through soluble mediator measurement, treatment can be initiated before full flare occurs, allowing use of gentler, non-steroidal therapies that act preventively rather than reactively, thereby reducing side effects while maintaining effective disease control.
Solution Approach 2:
The patent establishes a feedback loop where soluble mediator levels continuously monitor disease status, enabling dynamic adjustment of treatment intensity. This allows minimal effective therapy to be applied only when needed, avoiding unnecessary steroid exposure and associated harms.
3Reliability
If multiple soluble mediators are measured to improve detection accuracy, then prediction of flare becomes more reliable, but test complexity increases
Solution Approach 1:
The patent combines measurement of multiple soluble mediators (cytokines, chemokines, and other inflammatory/regulatory proteins) into an integrated assessment framework. By merging these measurements and evaluating their collective pattern rather than individual isolates, the system achieves high predictive accuracy while managing assay complexity through a unified testing approach.
Data Source
AI summary
The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.